T2 BIOSYSTEMS Lexington, MA, USA
RAPID WHOLE BLOOD DX
T2 MAGNETIC RESONANCE
T2 Biosystems uses T2 Magnetic Resonance (T2MR®) technology to identify pathogens and resistance markers directly in whole blood, independent of blood culture. CARB-X and T2 Biosystems will work together to develop high sensitivity, rapid diagnostic tests that are designed to identify the major bacterial species and resistance markers that cause sepsis. By getting patients on targeted therapy faster than ever before, clinicians can improve patient outcomes and reduce the overuse of precious antibiotics. Further, the products may also accelerate clinical trials and reduce the time to market for new antibiotics.
Current Development Stage: System Integration and Testing
CARB-X Investment: Initial investment of up to $1.1m with potential option payments up to $0.9m.
Initial CARB-X Investment Date: March 1, 2018
Read their Spotlight on Science